Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction
- 105 Downloads
HFmrEF has been recently proposed as a distinct HF phenotype. How HFmrEF differs from HFrEF and HFpEF according to age remains poorly defined. We aimed to investigate age-dependent differences in heart failure with mid-range (HFmrEF) vs. preserved (HFpEF) and reduced (HFrEF) ejection fraction.
Methods and results
42,987 patients, 23% with HFpEF, 22% with HFmrEF and 55% with HFrEF, enrolled in the Swedish heart failure registry were studied. HFpEF prevalence strongly increased, whereas that of HFrEF strongly decreased with higher age. All cardiac comorbidities and most non-cardiac comorbidities increased with aging, regardless of the HF phenotype. Notably, HFmrEF resembled HFrEF for ischemic heart disease prevalence in all age groups, whereas regarding hypertension it was more similar to HFpEF in age ≥ 80 years, to HFrEF in age < 65 years and intermediate in age 65–80 years. All-cause mortality risk was higher in HFrEF vs. HFmrEF for all age categories, whereas HFmrEF vs. HFpEF reported similar risk in ≥ 80 years old patients and lower risk in < 65 and 65–80 years old patients. Predictors of mortality were more likely cardiac comorbidities in HFrEF but more likely non-cardiac comorbidities in HFpEF and HFmrEF with < 65 years. Differences among HF phenotypes for comorbidities were less pronounced in the other age categories.
HFmrEF appeared as an intermediate phenotype between HFpEF and HFrEF, but for some characteristics such as ischemic heart disease more similar to HFrEF. With aging, HFmrEF resembled more HFpEF. Prognosis was similar in HFmrEF vs. HFpEF and better than in HFrEF.
KeywordsHFmrEF HFrEF HFpEF Age Prognosis
This study is supported by the Swedish Heart–Lung Foundation, the Swedish agreement between the government and the county councils concerning economic support for providing an infrastructure for research and education of doctors (ALF) and the Regional Development Fund, Västra Götaland County, Sweden (FOU-VGR).
Compliance with ethical standards
Conflict of interest
Xiaojing Chen: none. Gianluigi Savarese: none relevant for the present work. Unrelated to the present work: Research funding from the Italian Society of Cardiology on behalf of MSD Italia-Merck Sharp & Dohme Corporation; travel grants from Heart and Lung Foundation. Ulf Dahlström: none. Lars H. Lund: research grants to author’s institution: AstraZeneca, Novartis, Boston Scientiifc; speaker’s honoraria: AstraZeneca, Novartis, StJude, Merck; consulting honoraria: AstraZeneca, Novartis, Sanofi, Bayer, Vifor Pharma, Relypsa, Merck, HeartWare. Micheal Fu: none relevant for the present work. Unrelated to the present work: research funding and/or honoraria from AstraZeneca, Novartis, TRIOMED, and SERVIER.
- 1.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129–2200CrossRefGoogle Scholar
- 9.Tschope C, Birner C, Bohm M, Bruder O, Frantz S, Luchner A et al (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin Res Cardiol 107:1–19CrossRefGoogle Scholar
- 12.Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF et al (2016) Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail 4:464–472CrossRefGoogle Scholar
- 18.Bauer A, Khalil M, Ludemann M, Bauer J, Esmaeili A, De-Rosa R et al (2018) Creation of a restrictive atrial communication in heart failure with preserved and mid-range ejection fraction: effective palliation of left atrial hypertension and pulmonary congestion. Clin Res Cardiol 107:845–857CrossRefGoogle Scholar
- 23.Cohn JN, Johnson G (1990) Heart failure with normal ejection fraction. The V-HeFT study. Veterans administration cooperative study group. Circulation 81:48–53Google Scholar